Building a behavioral health company takes time. Some owners build with the intention of selling one day, and others build out of passion and decide to sell when they are ready to leave the business. Either way, you deserve to get the full value out of the company you built. Selling one is a wholly separate discipline, and most owners only get one chance to do it. The difference between a clean exit at a strong number and a process that stalls, re-trades, or quietly dies in diligence rarely comes down to the headline multiple. It comes down to preparation, cleaning up documentation, and diversifying the asset.
The behavioral health market is more constructive than it has been in recent years, and it is also more selective. Buyers who are targeting assets have a clear thesis on what they are pursuing. With a continually changing landscape across payers, clinical outcomes, and growing competition, buyers are arriving with precise diligence and a ready list of reasons to discount, scrutinize, and negotiate price. This is a market that rewards preparation and a controlled process while penalizing the opposite.
What follows is how we at VERTESS think about protecting and maximizing value, written for owners weighing a transaction within the next few years.
The Behavioral Health Company Seller's Playbook
Value in a sale is built long before it is negotiated. It comes from a clean business with real growth, healthy margins, a diversified and durable payer base, and a marketing engine that keeps the funnel full. The points below are how behavioral health company owners build and protect that value, roughly in the order the work tends to come.
Before You Go to Market
1. Sell into demand, not out of fatigue.
The best outcomes happen when you sell because the business has hit an inflection point a buyer will pay for, not because you are burned out, cash-strapped, or reacting to a reimbursement shock. The demand fundamentals are firmly on your side right now. More than one in five adults needs behavioral health care, demand continues to outpace a short-staffed workforce, and telehealth and value-based models are now permanent features of how that care is delivered.
The policy environment adds urgency to that window. Federal Medicaid funding faces roughly a trillion dollars in cuts over the next decade under the 2025 One Big Beautiful Bill Act, behavioral health sits in the optional-benefit category that states tend to trim first, and commercial payers have leaned harder into prior authorization and audits. None of this kills demand for care. What it does is raise the premium buyers place on payer durability and clean compliance, and raise the discount they apply to revenue that looks exposed. The smart read here is that the window for a successful transaction is open, the buyers are active, and the reimbursement environment is tightening behind you. That combination argues for moving from a position of strength rather than waiting for the picture to get easier, because it may not.
The ideal moment to sell is when your growth story is still ahead of you, your trailing financials are clean, and the macro window is open. This describes a lot of behavioral health today. If a transaction is anywhere on your horizon, the question is not whether the market will be perfect. It is whether you will be ready when it is good.
2. Recast earnings you can actually defend.
Adjusted EBITDA is usually the number a whole transaction hangs on, and behavioral health is full of legitimate normalizations. The standard ones are well understood: owner and provider compensation normalized to a market rate, personal and discretionary expenses run through the practice, family members on payroll above market, related-party rent where the owner leases the building to the practice through a separate entity, one-time costs such as legal settlements, recruiting, or a system implementation, and the carrying cost of de novo sites that are not yet contributing. Non-recurring income, like a one-time grant, comes back out the other way.
The adjustment that draws the most scrutiny, and the one owners most often misjudge, is compensation. A buyer is not paying for what an owner-clinician takes home today. They are underwriting what that provider will cost on a pro forma basis as an employed clinician at a market rate after close, and that normalized number can move EBITDA materially. It is worth understanding before a buyer hands you their version of it. Capture every defensible add-back, but know there is a line, and crossing it is expensive.
3. Payer mix and contract durability.
In normal periods, payer mix is just a line item in the model. In this environment, it is a primary driver of both your multiple and your certainty of close. Buyers are paying up for revenue they believe will still be there in three years, and discounting revenue they worry a state budget or a payer policy could erase.
Sub-verticals are diverging, and where you sit shapes who your buyers are and how you should position. Outpatient mental health remains the volume leader and the deepest buyer pool, driven by active platform builders rolling up add-ons. Autism and applied behavior analysis (ABA) still draw premium pricing for quality operators, though the sub-vertical now sits squarely in the reimbursement and compliance crosshairs, with several states moving on rates and federal payment integrity reviews intensifying. Interventional psychiatry is one of the fastest-moving corners of the market, as transcranial magnetic stimulation (TMS), Spravato, and ketamine services consolidate into multi-modal networks. Substance use, by contrast, has cooled meaningfully, with deal volume well off its post-COVID peak.
In practice, durability means a balanced commercial and Medicaid mix rather than heavy single-payer concentration, contracted rates you can show holding up, and durable agreements that travel with the business through a transaction. Long-term or sole-source contracts are worth real money right now, precisely because they answer one of a buyer's biggest questions before it is even asked. If you have one, lead with it.
4. Survive the quality of earnings review.
A third-party quality of earnings (QofE) review now shows up in essentially every competitive process. Once a buyer's team catches a single unsupportable adjustment, they tend to apply that same skepticism to every other number on the page. The goal is a clean, fully documented recast that survives that review intact, because an add-back that does not hold up ends up costing you more than its own dollar value.
5. Turn your clinical team into an asset, not a key-man risk.
Behavioral health is a labor business, and the scarcest input is licensed clinicians who stay: prescribers, BCBAs, and credentialed therapists. Two things move value here. First, reduce the dependence on you, the owner. If the practice cannot run a week without you in the building, a buyer sees risk rather than a platform. Second, show retention and bench depth. Provider turnover, open credentialing files, and a roster of contractors who could walk all read as fragility.
A stable, employed, well-credentialed team with a real second layer of clinical leadership reads as something a buyer can scale. Get retention agreements, compensation structures, and credentialing files in order well before you go to market, not in the middle of diligence.
6. Let your outcomes and compliance do the selling.
Two years ago, measurement-based care and accreditation were nice to have. In today's audit and scrutiny environment, they are a value driver on the upside and a risk eliminator on the downside. Quality of care has become a commercial issue.
Payers and regulators increasingly want providers to track and report concrete treatment results, and behavioral health outcome measures are now actively enforced on the Medicaid and CHIP side. The commercial side is raising the bar too, with carriers leaning harder on documentation, medical necessity, and demonstrated results. Cigna's Evernorth recently removed prior authorization for TMS — a signal that payers are easing access for proven treatments, and one that rewards operators who have already built the clinical infrastructure to document outcomes.
Documented clinical outcomes set you apart in a crowded field and support a premium, while clean billing, tight documentation, and accreditation through CARF or the Joint Commission clear away the red flags that tend to surface at the worst possible moment in diligence. In the sub-verticals drawing the most scrutiny — autism and ABA in particular — compliance has become a pricing input. Treat it like one.
7. Build platform infrastructure.
Deal volume in behavioral health was well over 100 transactions in 2025, and that pace has carried into 2026. But the spread between what buyers pay for top assets and what they pay for average ones has widened significantly. A scaled platform with clean financials, accreditation, and a diversified payer base commands a meaningful premium. A smaller, single-site, owner-dependent practice in the same sub-vertical can be valued at a fraction of that.
The widening valuation gap is, at its core, a gap between businesses that look like platforms and businesses that look like practices. Centralized revenue cycle management, a real intake engine, a single source of truth in your EHR, and back-office functions that do not live in your head are what separate a platform valuation from a practice valuation. You do not need to be a national chain, but you do need to look like something a buyer can plug capital into and grow without rebuilding the foundation first. If you are planning a sale in the next few years, the infrastructure you build now is some of the highest-return work you can do, because it moves the multiple, not just the earnings.
The Behavioral Health Transaction Process
8. Run a competitive sale.
A competitive process is the most reliable way to create leverage, and leverage is what turns a fair offer into the right one. When several credible buyers are evaluating the same asset on a similar timeline, it is the process itself — rather than any single conversation — that establishes value. A real process also gives you a choice. Instead of reacting to one offer, you can compare buyers on what actually matters: price and terms, of course, but also strategic fit, the growth story under that partner, and the probability of actually getting to close.
The best number and the best partner are not always the same party. Behavioral health M&A is complex, and plenty of deals come apart for reasons that have nothing to do with price, so probability of close deserves real weight. Experienced buyers with capital, an existing platform, and a track record of closing improve the odds that a signed deal becomes a closed one. The job of a well-run process is to surface those buyers, keep enough of them engaged, and let you choose from a position of strength.
After the LOI Is Signed
9. Keep performing.
The stretch between a signed letter of intent (LOI) and a closed deal is where value quietly leaks, usually through one of two avoidable mistakes. The first is mentally checking out, letting the business drift, and watching performance soften right when the buyer is confirming the numbers they agreed to pay for. A dip in trailing results during diligence is the most common justification for a price re-trade, and the reduction is almost always larger than the shortfall that triggered it. Run the business as if the deal might not happen, because until it closes, it might not.
The second mistake is treating the LOI as the finish line and giving up the leverage you have left. The no-shop period protects the buyer, so your protection has to come from a complete, well-papered deal and a disciplined posture all the way through signing. Negotiate the terms that matter while you still can, and keep the business strong enough that you are negotiating from strength, not relief.
A Final Thought
The behavioral health owners who maximize value in this market are not necessarily the ones with the best clinical reputation or even the highest growth rate. They are the ones who treated the sale as its own project, built the business to be bought well before they needed to, and ran a process that created real competition for it. In a market that is constructive but selective, and tightening behind you on reimbursement, preparation really is the entire game.
That is the work we do at VERTESS. We represent owners across the healthcare and human services landscape on the full arc of a sell-side transaction — from positioning and earnings recast through process management and close — with deep, sub-vertical expertise in behavioral health. If a transaction is anywhere in your future, the decisions that shape your outcome are made earlier than most owners expect. That is where we want to be involved.